Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 335

Oncology

Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Conditions:   Advanced Malignant Neoplasm;   Breast Cancer;   Ovarian Cancer;   Homologous Recombination Deficiency
Interventions:   Drug: AMXI-5001:Dose Escalation Phase I;   Drug: AMXI-5001: Dose Expansion Phase II
Sponsor:   AtlasMedx, Incorporated
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 8, 2020 / by / in
Patient-centered Communication About Healthy Weight in Early Breast Cancer
Condition:   Breast Cancer
Intervention:   Other: Focus Group
Sponsor:   UNC Lineberger Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 8, 2020 / by / in
Target Rare Cancer Knowledge
Conditions:   Rare Cancers;   Cholangiocarcinoma;   Cancer of Unknown Primary Site
Intervention:   Diagnostic Test: Foundation Medicine blood and tissue testing
Sponsors:   TargetCancer Foundation;   Foundation Medicine
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 8, 2020 / by / in
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Condition:   Solid Tumor, Adult
Intervention:   Drug: Leronlimab
Sponsors:   CytoDyn, Inc.;   Amarex Clinical Research
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 8, 2020 / by / in
Naxitamab and GM-CSF in People With Neuroblastoma
Condition:   High-Risk Neuroblastoma
Intervention:   Biological: Naxitamab/GM-CSF
Sponsor:   Memorial Sloan Kettering Cancer Center
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 7, 2020 / by / in
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies
Condition:   T Cell Lymphoma
Intervention:   Biological: CTX130
Sponsor:   CRISPR Therapeutics AG
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 7, 2020 / by / in
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Conditions:   Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8;   Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage 0 Gastric Cancer AJCC v8;   Clinical Stage I Esophageal Adenocarcinoma AJCC v8;   Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage I Gastric Cancer AJCC v8;   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage II Gastric Cancer AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIA Gastric Cancer AJCC v8;   Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastric Cancer AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Hepatobiliary Neoplasm;   Malignant Digestive System Neoplasm;   Malignant Female Reproductive System Neoplasm;   Malignant Genitourinary System Neoplasm;   Malignant Neoplasm;   Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage 0 Gastric Cancer AJCC v8;   Pathologic Stage I Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage I Gastric Cancer AJCC v8;   Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IA Gastric Cancer AJCC v8;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IB Gastric Cancer AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage II Gastric Cancer AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIA Gastric Cancer AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIB Gastric Cancer AJCC v8;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Stage 0 Colorectal Cancer AJCC v8;   Stage 0a Bladder Cancer AJCC v8;   Stage 0is Bladder Cancer AJCC v8;   Stage I Bladder Cancer AJCC v8;   Stage I Cervical Cancer AJCC v8;   Stage I Colorectal Cancer AJCC v8;   Stage I Ovarian Cancer AJCC v8;   Stage I Prostate Cancer AJCC v8;   Stage I Renal Cell Cancer AJCC v8;   Stage I Uterine Corpus Cancer AJCC v8;   Stage IA Cervical Cancer AJCC v8;   Stage IA Ovarian Cancer AJCC v8;   Stage IA Uterine Corpus Cancer AJCC v8;   Stage IA1 Cervical Cancer AJCC v8;   Stage IA2 Cervical Cancer AJCC v8;   Stage IB Cervical Cancer AJCC v8;   Stage IB Ovarian Cancer AJCC v8;   Stage IB Uterine Corpus Cancer AJCC v8;   Stage IB1 Cervical Cancer AJCC v8;   Stage IB2 Cervical Cancer AJCC v8;   Stage IC Ovarian Cancer AJCC v8;   Stage II Bladder Cancer AJCC v8;   Stage II Cervical Cancer AJCC v8;   Stage II Colorectal Cancer AJCC v8;   Stage II Ovarian Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage II Renal Cell Cancer AJCC v8;   Stage II Uterine Corpus Cancer AJCC v8;   Stage IIA Cervical Cancer AJCC v8;   Stage IIA Colorectal Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIA1 Cervical Cancer AJCC v8;   Stage IIA2 Cervical Cancer AJCC v8;   Stage IIB Cervical Cancer AJCC v8;   Stage IIB Colorectal Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Colorectal Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8;   Stage III Bladder Cancer AJCC v8;   Stage III Cervical Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage III Renal Cell Cancer AJCC v8;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8;   Stage IIIA Cervical Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Bladder Cancer AJCC v8;   Stage IIIB Cervical Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Bladder Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
Interventions:   Procedure: Patient Monitoring;   Other: Questionnaire Administration
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 7, 2020 / by / in
Perioperative Care in the Cancer Patient -1, ARCA-1 Study
Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm
Interventions:   Other: Best Practice;   Other: Medical Chart Review
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 7, 2020 / by / in
Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic
Conditions:   COVID-19 Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm
Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 6, 2020 / by / in
Study of RP-3500 in Advanced Solid Tumors
Condition:   Advanced Solid Tumor, Adult
Interventions:   Drug: RP-3500;   Drug: Talazoparib: oral PARP inhibitor
Sponsor:   Repare Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 5, 2020 / by / in